Answers are grounded in this paper and cite their sources.
Despite over 524,592 COVID-19 papers indexed in PubMed as documented in our synthesis compilation and widespread vaccine deployment over the past six years, COVID-19 has caused more than 7.11 million officially reported deaths globally—with WHO excess mortality estimates reaching 14.83 million for 2020–2021 alone and cumulative excess death estimates spanning 18.5 to 35.2 million [1, 2, 3, 4, 5, 6]—while leaving an estimated 400 million individuals worldwide with Long COVID (post-acute sequelae of SARS-CoV-2, or PASC) at an approximate $1 trillion annual economic cost [1, 5]. To address the absence of a phase-independent mechanistic therapy, we propose and computationally evaluate a unified host-directed therapeutic framework centered on co-activating the cellular stress-response regulators p53 and NRF2 [1]. Across acute and post-acute phases, SARS-CoV-2 suppresses p53 and NRF2 signaling, depleting miR-29 (which harbors 11 conserved binding sites on the SARS-CoV-2 genome and directly targets IFNG) and miR-145 (which restrains Tissue Factor F3, Semaphorin-3A Sema3a, Granzyme K GZMK, and MYC) while hyperactivating NF-κB [1, 7, 8, 9, 10]. This upstream collapse drives persistent elevations in IFN-γ, Tissue Factor (TF), Sema3a, and Granzyme K (GzmK), promoting myocarditis, thromboembolism, myocardial dysfunction, and age-related tissue remodeling independently of age-associated immune dysfunction [1, 11, 12, 13]. Stiff ordinary differential equation (ODE) simulations (solve_ivp/BDF) parameterized from published turnover kinetics demonstrate that simulated p53/NRF2 co-activation induces a sharp bifurcation switch near an agonist threshold of Uth = 0.4–0.6 under persistent antigenic stimulation, producing a 13.75-fold recovery of miR-29 and a 54.39-fold recovery of miR-145 while suppressing NF-κB by 94.0% and reducing IFN-γ, TF, Sema3a, and GzmK by 98.3% to 99.1% in locked PASC steady states [14]. In an aggressive acute infection simulation (rv = 0.12 h-1), therapy initiated at 24 h lowers 168 h viral load by 46.2% and suppresses the four terminal effectors by 92.0% to 95.1% [14]. Because these quantitative dynamics derive from in silico modeling and cross-study synthesis, key evidentiary caveats remain—including incomplete extraction of individual duplex coordinates for all 11 miR-29 viral sites, cross-species differences in miR-145 validation for GZMK and Sema3a, compartment-specific p53 paradoxes, and the absence of prospective randomized trials testing combined p53/NRF2 agonism in PASC [1, 10, 15].
No takes yet. Share an insight, caveat, or question.
Boominathan Lakshmanane (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: